Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid Long COVID-19 Prevention Trial (Norway)
2023-510337-29-00Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and post-COVID syndrome comparing Paxlovid with Placebo (2 arms). Planned start Jun 2024; status: authorised.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)post-COVID syndrome
Beyond the preview
Go deeper on 2023-510337-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510337-29-00.